NPSP NPS Pharmaceuticals, Inc. featured news, full reports, and detailed charts
NPS Pharmaceuticals, Inc. (NPSP) Wrap Up:
We are a biopharmaceutical company engaged in the development of specialty therapeutics to treat gastrointestinal (GI) and endocrine disorders with high unmet medical need. Our lead clinical programs involve two proprietary proteins to restore or replace biological function: GATTEX™ (teduglutide) and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection). GATTEX is an analog of GLP-2, a protein involved in the regeneration and repair of the intestinal lining, and is in Phase 3 clinical development for short bowel syndrome (SBS). SBS affects patients who have had 50% or more of their small intestine removed. Given GATTEX's activity in promoting gastrointestinal repair, we are also evaluating its role in treating other GI conditions associated with intestinal failure, specifically GI mucositis (GIM), necrotizing enterocolitis (NEC), and Crohn's disease. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f05%2f19%2f0001136261-08-000084.html#FIS_BUSINESS"NPS Pharmaceuticals, Inc. (NPSP:NASDAQ)
Snapshot of NPS Pharmaceuticals, Inc. (NPSP)
|
OPEN
$3.05
|
PREVIOUS CLOSE
$3.09
|
|
|
DAY HIGH
$3.10
|
DAY LOW
$3.00
|
|
|
52 WEEK HIGH
12/9/08 - $7.00
|
52 WEEK LOW
06/1/09 - $2.74
|
|
|
MARKET CAP
149.2M
|
AVERAGE VOLUME 3 mo
229.0K
|
|
|
DILUTED EPS TTM
$-0.51
|
SHARES OUTSTANDING
48.4M
|
|
|
NPSP Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
NPSP Top Compensated Officers
Executives, Board Directors
Key developments for NPS Pharmaceuticals, Inc. (NPSP)
NPS Pharmaceuticals Inc. reported unaudited consolidated cash flow results for the nine months ended September 30, 2009. For the period, the company net cash provided by operating activities of $3,686,000 compared to net cash used in operating activities of $6,064,000 for the same period a year ago.
NPS Pharmaceuticals Inc. reported earnings results for third quarter and nine months ended September 30, 2009. For the quarter, the company reported operating income of $3,964,000, interest income $374,000, loss before income tax benefit $7,801,000, net loss of $7,766,000 or $0.16 diluted earnings per share on revenues of $20,119,000 compared to operating income of $14,545,000, interest income $983,000, loss before income tax benefit $11,482,000, net loss of $11,359,000 or $0.24 diluted earnings per share on revenues of $26,075,000, for the same period a year ago. For the nine months, the company reported operating income of $23,668,000, interest income $1,374,000, loss before income tax benefit $16,934,000, net loss of $15,885,000 or $ 0.33 diluted earnings per share on revenues of $62,097,000 compared to operating income of $35,967,000, interest income $3,804,000, loss before income tax benefit $23,469,000, net loss of $23,249,000 or $0.49 diluted earnings per share on revenues of $78,214,000, for the same period a year ago.
NPS Pharmaceuticals, Inc., Q3 2009 Earnings Call, Nov-04 2009
NPSP Competitors
| Company | Last | Change | |
| No competitor information is available for NPSP. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | NPSP | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 1.7x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | NM | Not Meaningful |
|
NPSP |
||
NPSP transactions
| Type Date |
Target |
|
Private Placement
August 5, 2009 |
-- |